PAD and DVT Drugs crossword Flashcards
IV thrombin inhibitor for the prophylaxis and treatment of heparin induced thrombocytopenia; classic answer but DOACs may eventually replace
argatroban
released by thrombin, polymerized form is a substrate for plasmin
fibrin
generic reference to drug class that is first-line therapy for decreasing risk for PAD
statins
factor Xa decoy recently approved as a reversal agent for factor Xa inhibitors rivaroxaban and apixaban
andexanet alfa
dabigatran was found to be inferior to warfin at inhibiting thromboembolism for this type of heart valve
mechanical
orally active and reversible direct inhibitor of thrombin
dabigatran
a direct inhibitor of activated factor X, it therefore rapidly inhibits the generation of thrombin from prothrombin; similar drugs end in -xaban
rivaroxaban
a synthetic peptide similar to leech anticoagulant hirudin, it is a direct inhibitor of thrombin, but class as a whole has had limited use since it must be administered intravenously and much more expensive than heparin
bivalirudin
irreversibly blocks the synthesis of thromboxane A2 by platelets; one of the agents that promotes the activation and aggregation of platelets… this is beneficial in patients with PAD, but can also increase risk of bleeding; also can displace warfarin bound to albumin to increase its effects/cause bleeding
aspirin
assay that can be used to measure anticoagulation for drugs such as rivaroxaban
antixa
what is the reason patients must be transitioned to warfarin therapy rather than abruptly started on it?
it could cause necrosis of the skin
humanized antibody recently available to neutralize/serve as an antidote for dabigatran
idarucizumab
element of treatment strategy when switching from DOAC to warfarin but not when switching from one DOAC to another
overlap
can be used to assess anticoagulation cause by dabigatran
diluted thrombin time
carbamazepine, phenytoin, and phenobarbital decrease the effects of warfarin because they do this to the synthesis of its metabolic enzymes
induce